[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100425430":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":30,"responsibleParty":142,"collaborators":19,"id":144,"slug":145,"hasResults":146,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":146,"sex":152,"minAge":153,"maxAge":154,"enrollmentInfo":155,"targetDuration":19,"studyType":158,"phases":159,"briefSummary":162,"conditions":163,"keywords":165,"overallStatus":33,"whyStopped":19,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":180},{"fullName":5,"class":6},"Kamau Therapeutics","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"nula-cel Drug Product","EXPERIMENTAL","nula-cel Drug Product is a human autologous CRISPR-Cas9 edited and sickle mutation-corrected HSPC product.",[13],"Genetic: nula-cel Drug Product",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"GENETIC","nula-cel is administered via IV infusion following a myeloablative conditioning regimen",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Matthew Porteus, MD, PhD","STUDY_DIRECTOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":19,"email":29},"Restore Clinical Study Support","CONTACT","650-442-2283","RestoreStudySupport@kamautx.com",[31,53,75,92,113,125],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Children's Hospital Los Angeles","RECRUITING","Los Angeles","California","90027","United States","US",{"type":40,"coordinates":41},"Point",[42,43],-118.24368,34.05223,{"lat":43,"lon":42},[46,50],{"name":47,"role":27,"phone":48,"phoneExt":19,"email":49},"Bridget Bailey","323-361-7382","brbailey@chla.usc.edu",{"name":51,"role":52,"phone":19,"phoneExt":19,"email":19},"Ashley Gray, MD","PRINCIPAL_INVESTIGATOR",{"facility":54,"status":33,"city":55,"state":35,"zip":56,"country":37,"countryCode":38,"cosmosGeoPoint":57,"geoPoint":61,"contacts":62},"Lucile Packard Children's Hospital","Palo Alto","94304",{"type":40,"coordinates":58},[59,60],-122.14302,37.44188,{"lat":60,"lon":59},[63,66,70,72],{"name":64,"role":27,"phone":19,"phoneExt":19,"email":65},"Stanford Intake Team","scgt_clinical_trials_office@lists.stanford.edu",{"name":67,"role":27,"phone":68,"phoneExt":19,"email":69},"Kat Joseph, BSN, RN","650-725-9032","kjoseph3@stanford.edu",{"name":71,"role":52,"phone":19,"phoneExt":19,"email":19},"May Chien, MD",{"name":73,"role":74,"phone":19,"phoneExt":19,"email":19},"David Shyr, MD","SUB_INVESTIGATOR",{"facility":76,"status":33,"city":77,"state":78,"zip":79,"country":37,"countryCode":38,"cosmosGeoPoint":80,"geoPoint":84,"contacts":85},"Washington University","St Louis","Missouri","63110",{"type":40,"coordinates":81},[82,83],-90.19789,38.62727,{"lat":83,"lon":82},[86,90],{"name":87,"role":27,"phone":88,"phoneExt":19,"email":89},"Maggie Nash","314-273-5936","nashm@wustl.edu",{"name":91,"role":52,"phone":19,"phoneExt":19,"email":19},"John F Dipersio, MD, PhD",{"facility":93,"status":33,"city":94,"state":94,"zip":95,"country":37,"countryCode":38,"cosmosGeoPoint":96,"geoPoint":100,"contacts":101},"Columbia University Irving Medical Center","New York","10032",{"type":40,"coordinates":97},[98,99],-74.00597,40.71427,{"lat":99,"lon":98},[102,106,109,111],{"name":103,"role":27,"phone":104,"phoneExt":19,"email":105},"Camila Barros","212-342-3884","cb4149@cumc.columbia.edu",{"name":107,"role":27,"phone":19,"phoneExt":19,"email":108},"Elizabeth Shelton","eas2304@cumc.columbia.edu",{"name":110,"role":52,"phone":19,"phoneExt":19,"email":19},"Marcus Mapara, MD",{"name":112,"role":52,"phone":19,"phoneExt":19,"email":19},"Monica Bhatia, MD",{"facility":114,"status":33,"city":94,"state":94,"zip":115,"country":37,"countryCode":38,"cosmosGeoPoint":116,"geoPoint":118,"contacts":119},"Memorial Sloan Kettering","10065",{"type":40,"coordinates":117},[98,99],{"lat":99,"lon":98},[120,123],{"name":121,"role":27,"phone":19,"phoneExt":19,"email":122},"Maria Paes Pena","paespem@mskcc.org",{"name":124,"role":52,"phone":19,"phoneExt":19,"email":19},"Jaap Jan Boelens, MD, PhD",{"facility":126,"status":33,"city":127,"state":128,"zip":129,"country":37,"countryCode":38,"cosmosGeoPoint":130,"geoPoint":134,"contacts":135},"Nationwide Children's Hospital","Columbus","Ohio","43205",{"type":40,"coordinates":131},[132,133],-82.99879,39.96118,{"lat":133,"lon":132},[136,139],{"name":137,"role":27,"phone":19,"phoneExt":19,"email":138},"Dalena Sanderson","Dalena.Sanderson@nationwidechildrens.org",{"name":140,"role":27,"phone":19,"phoneExt":19,"email":141},"Lauren Rayman","lauren.rayman2@nationwidechildrens.org",{"type":143,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100425430","phase-1-gene-correction-in-autologous-cd34-hematopoietic-stem-cells-hbs-to-hba-to-treat-severe-sickle-cell-disease-100425430",false,"NCT04819841","Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease","A Phase I\u002FII Study of Nula-cel in Autologous CD34+ Hematopoietic Stem Cells to Convert HbS to HbA for Treating Severe Sickle Cell Disease","Restore","Inclusion Criteria:\n\n* ≥12 to ≤ 40 years\n* Severe disease, as defined by having experienced at least one of the following SCD-related events despite appropriate supportive care measures:\n* recurrent severe VOC (≥ 4 episodes in the preceding 2 years)\n* ACS (≥ 2 episodes in the prior 2 years with at least one episode in the past year)\n* Lansky\u002FKarnofsky performance status of ≥ 80\n\nExclusion Criteria:\n\n* Available 10\u002F10 HLA-matched sibling donor\n* Prior HSCT or gene therapy\n* Prior or current malignancy or myeloproliferative or a significant coagulation or immunodeficiency disorder\n* Clinically significant and active bacterial, viral, fungal or parasitic infection\n* Pregnancy or breastfeeding in a postpartum female\n* Presence of a chromosomal abnormality\u002Fmutation that may put the participant at an increased risk for MDS or AML per investigator's judgment","ALL","12 Years","50 Years",{"count":156,"type":157},15,"ESTIMATED","INTERVENTIONAL",[160,161],"PHASE1","PHASE2","This study is a first-in-human, single-arm, open-label Phase I\u002FII study of nula-cel in approximately 15 participants, diagnosed with severe Sickle Cell Disease. The primary objective is to evaluate safety of the treatment in this patient population, as well as preliminary efficacy and pharmacodynamic data.",[164],"Sickle Cell Disease",[166,167,168,169,170],"sickle cell disease","sickle cell anemia","gene correction","gene therapy","CRISPR","2026-06-30",{"date":173,"type":174},"2026-07-02","ACTUAL",{"date":176,"type":174},"2021-11-15",{"date":178,"type":157},"2028-12-31",{"name":5,"class":6},6]